Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 3, 2013, Pages 256-268

  Matosin, Natalie ^a,b   Newell, Kelly A ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Schizophrenia Research Institute (SRI)   (Australia)

Author keywords

Antipsychotic; Metabotropic glutamate receptor 5; MGlu5; MGluR5; NMDA receptor; PAM; Positive allosteric modulator; Schizophrenia

Indexed keywords

CLOZAPINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; OLANZAPINE; PLACEBO; RO 4917523; UNCLASSIFIED DRUG;

COMPLEX FORMATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; FRAGILE X SYNDROME; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84872735105     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.12.005     Document Type: Review

References (147)

1. Abe S., Suzuki T., Ito T., Yamaguchi M., Baba A., Hori T., Kurita H., Shiraishi H., Okado N. Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain. Neuropsychopharmacology 2001, 25:173-184.
2. Agnati L.F., Guidolin D., Albertin G., Trivello E., Ciruela F., Genedani S., Tarakanov A., Fuxe K. An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A2A, dopamine D2, cannabinoid CB1, and metabotropic glutamate mGlu5 receptors. Journal of Receptor and Signal Transduction Research 2010, 30:355-369.
3. Alagarsamy S., Rouse S.T., Junge C., Hubert G., Gutman D., Smith Y., Conn P.J. NMDA-induced phosphorylation and regulation of mGluR5. Pharmacology Biochemistry and Behavior 2002, 73:299-306.
4. Alagarsamy S., Saugstad J., Warren L., Mansuy I.M., Gereau R.W., Conn P.J. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology 2005, 49(Suppl.):135-145.
5. Anborgh P.H., Godin C., Pampillo M., Dhami G.K., Dale L.B., Cregan S.P., Truant R., Ferguson S.S.G. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. Journal of Biological Chemistry 2005, 280:34840-34848.
6. Andersson C., Chakos M., Mailman R., Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. The Psychiatric Clinics of North America 1998, 21:151-179.
7. Ango F., Robbe D., Tu J.C., Xiao B., Worley P.F., Pin J.P., Bockaeart J., Fagni L. Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons. Molecular and Cellular Neurosciences 2002, 20:323-329.
8. Arnold S.E., Talbot K., Hahn C.G. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Progress in Brain Research 2004, 147:319-345.
9. Attucci S., Carla V., Mannaioni G., Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. British Journal of Pharmacology 2001, 132:799-806.
10. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. Journal of Neuroscience 2000, 20:7871-7879.
11. Ayala J.E., Chen Y., Banko J.L., Sheffler D.J., Williams R., Telk A.N., Watson N.L., Xiang Z., Zhang Y., Jones P.J. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34:2057-2071.
12. Bakshi V.P., Geyer M. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995, 122:198-201.
13. Bakshi V.P., Tricklebank M., Neijt H.C., Lehmann-Masten V., Geyer M.A. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-d-aspartate receptor antagonists in rats. Journal of Pharmacology and Experimental Therapeutics 1999, 288:643-652.
14. Balázs R., Miller S., Romano C., De Vries A., Chun Y., Cotman C.W. Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacology, properties and agonist regulation. Journal of Neurochemistry 1997, 69:151-163.
15. Balschun D., Zuschratter W., Wetzel W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006, 142:691-702.
16. Benquet P., Gee C.E., Gerber U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. Journal of Neuroscience 2002, 22:9679.
17. Brodkin J., Bradbury M., Busse C., Warren N., Bristow L.J., Varney M.A. Reduced stress-induced hyperthermia in mGluR5 knockout mice. European Journal of Neuroscience 2002, 16:2241-2244.
18. Busse C.S., Brodkin J., Tattersall D., Andersen J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., Cosford N.D.P. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP) in rodent models of anxiety. Neuropharmacology 2004, 29:1971-1979.
19. Brody S., Dulawa S., Conquet F., Geyer M. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Molecular Psychiatry 2004, 9:35-41.
20. Campbell U.C., Lalwani K., Hernandez L., Kinney G.G., Conn P.J., Bristow L.J. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 2004, 175:310-318.
21. Chan M.H., Chiu P.H., Sou J.H., Chen H.H. Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology 2008, 198:141-148.
22. Chartoff E.H., Heusner C.L., Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005, 30:1324-1333.
23. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neuroscience 2001, 4:873-874.
24. Clifton N.E., Morisot N., Girardon S., Millan M.J., Loiseau F. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl) 2012, epub ahead of print, Sept. 16, 2012.
25. Cochran S.M., Fujimura M., Morris B.J., Pratt J.A. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 2002, 46:206-214.
26. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacological Sciences 2009, 30:25-31.
27. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology 1995, 120:67-74.
28. + ATPase-α1 in the prefrontal cortex of subjects with schizophrenia. Schizophrenia Research 2011, 128:7-14.
29. Coward D. General pharmacology of clozapine. British Journal of Psychiatry. Supplement 1992, 17:5-11.
30. Darrah J.M., Stefani M.R., Moghaddam B. Interaction of N-methyl-d-aspartate and Group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behavioural Pharmacology 2008, 19:225-234.
31. Deschwanden A., Karolewicz B., Feyissa A.M., Treyer V., Ametamey S.M., Johayem A., Cyrill B., Yves P.A., Sovago J., Stockmeier C.A., Buck A., Hasler G. Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C] ABP688 positron emission tomography and postmortem study. American Journal of Psychiatry 2011, 168:727-734.
32. Devon R., Anderson S., Teague P., Muir W., Murray V., Pelosi A., Blackwood D., Porteous D. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Molecular Psychiatry 2001, 6:311.
33. Doherty A.J., Palmer M.J., Bortolotto Z.A., Hargreaves A., Kingston A.E., Ornstein P.L., Schoepp D.D., Lodge D., Collingridge G.L. A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology 2000, 131:239-244.
34. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., Jane D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 1997, 36:265-267.
35. Du Bois T.M., Huang X.F. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Research Reviews 2007, 53:260-270.
36. Engmann O., Tibor H., Pidsley R., Troakes C., Bernstein H.G., Kreutz M.R., Mill J., Nikolic M., Giese K.P. Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain 2011, 134:2408-2421.
37. Fowler S.W., Ramsey A.K., Walker J.M., Serfozo P., Olive M.F., Schachtman T.R., Simonyi A. Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats. Neurobiology of Learning and Memory 2011, 95:73-79.
38. Francesconi A., Duvoisin R.M. Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. Journal of Biological Chemistry 1998, 273:5615-5624.
39. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., Roberts D.C.S., Langel U., Genedani S., Ferraro L., de la Calle A., Narvaez J., Tanganelli S., Woods A., Agnati L.F. Receptor-receptor interactions within receptor mosaics: impact on neuropsychopharmacology. Brain Research Reviews 2008, 58:415-452.
40. Gastambide F., Cotel M.C., Gilmour G., O'Neill M.J., Robbins T.W., Tricklebank M.D. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 2012, 37:1057-1066.
41. Gastambide F., Gilmour G., Robbins T.W., Tricklebank M.D. The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropsychopharmacology 2013, 64:240-247.
42. Geddes A.E., Huang X.F., Newell K.A. Reciprocal signalling between NR2 subunits of the NMDA receptor and Neuregulin1 and their role in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 4:896-904.
43. Gilmour G., Broad L.M., Wafford K.A., Britton T., Colvin E.M., Fivush A., Gastambide F., Getman B., Heinz B.A., McCarthy A.P., Prieto L., Shanks E., Smith J.W., Taboada L., Edgar D.M., Tricklebank M.D. In vitro characterisation of the novel positive allosteric modulators of the mGlu 5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 2013, 64:224-239.
44. Goff D.C., Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research 1997, 27:157-168.
45. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. The International Journal of Neuropsychopharmacology 2009, 12:45-60.
46. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biology 2003, 4:117.
47. Groveman B.R., Feng S., Fang X.Q., Pflueger M., Lin S.X., Bienkiewicz E.A., Yu X. The regulation of N-methyl-d-aspartate receptors by Src kinase. FEBS Journal 2012, 279:20-28.
48. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., Meador Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57:123-131.
49. Gürkan C.K., Hagerman R.J. Targeted treatments in autism and fragile X syndrome. Research in Autism Spectrum Disorders 2012, 6:1311-1320.
50. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neuroscience 2002, 5:405-414.
51. Harrison P.J., Lyon L., Sartorius L.J., Burnet P., Lane T.A. Review: the group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. Journal of Psychopharmacology 2008, 22:308-322.
52. Henry S., Lehmann-Masten V., Gasparini F., Geyer M., Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43:1199-1209.
53. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003, 27:1113-1123.
54. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004, 29:1259-1269.
55. Homayoun H., Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cerebral Cortex 2006, 16:93.
56. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 2007, 27:11496-11500.
57. Horio, M., Fujita, Y., Hashimoto, K., in press. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundamental and Clinical Pharmacology.
58. Hu J.-H., Yang L., Kammermeier P.J., Moore C.G., Brakeman P.R., Tu J., Yu S., Petralia R.S., Li Z., Zhang P.-W., Park J.M., Dong X., Xiao B., Worley P.F. Preso1 dynamically regulates group I metabotropic glutamate receptors. Nature Neuroscience 2012, 15:836-844.
59. Huang Y.Q., Lu W.Y., Ali D.W., Pelkey K.A., Pitcher G.M., Lu Y.M., Aoto H., Roder J.C., Sasaki T., Salter M.W., MacDonald J.F. CAKβ/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 2001, 29:485-496.
60. Iasevoli F., Polese D., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis. Neuroscience Letters 2007, 416:1-5.
61. Iasevoli F., Fiore G., Cicale M., Muscettola G., de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Research 2010, 177:255-260.
62. Inta D., Filipovic D., Lima-Ojeda J.M., Dormann C., Pfeiffer N., Gasparini F., Gass P. The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug. Neuropharmacology 2012, 62:2034-2039.
63. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148:1301.
64. Jia Z., Lu Y., Henderson J., Taverna F., Romano C., Abramow-Newerly W., Wojtowicz J.M., Roder J. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learning and Memory 1998, 5:331-343.
65. Kammermeier P.J., Worley P.F. Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proceedings of the National Academy of Science 2007, 104:6055-6060.
66. Kane J. Addressing side effects from antipsychotic treatment in schizophrenia. The Journal of Clinical Psychiatry 2011, 72:e07.
67. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Research Bulletin 2010, 83:108-121.
68. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Chen T.B., Wisnoski D.D., Lindsley C.W., Tiller P.R., Smith S., Jacobson M.A., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., Williams D.L. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. Journal of Pharmacology and Experimental Therapeutics 2005, 313:199-206.
69. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. Journal of Neuroscience 2006, 26:1604-1615.
70. Kinon B.J., Zhang L., Millen B.A., Osuntokun O.O., Williams J.E., Kollack-Walker S., Jackson K., Kryzhanovskaya L., Jarkova N. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. Journal of Clinical Psychopharmacology 2011, 31:349-355.
71. Kitano J., Kimura K., Yamazaki Y., Soda T., Shigemoto R., Nakajima Y., Nakanishi S. Tamalin, a PDZ domain-containing protein, links a protein complex formation of group 1 metabotropic glutamate receptors and the guanine nucleotide exchange factor cytohesins. Journal of Neuroscience 2002, 22:1280-1289.
72. Lang U.E., Puls I., Muller D.J., Strutz-Seebohm N., Gallinat J. Molecular mechanisms of schizophrenia. Cellular Physiology and Biochemistry 2007, 20:687-702.
73. Large C.H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. Journal of Psychopharmacology 2007, 21:283.
74. Lecourtier L., Homayoun H., Tamagnan G., Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biological Psychiatry 2007, 62:739-746.
75. Lee J.H., Lee J., Choi K.Y., Hepp R., Lee J.-Y., Lim M.K., Chatani-Hinze M., Roche P.A., Kim D.G., Ahn Y.S., Kim C.H., Roche K.W. Calmodulin dynamically regulates the trafficking of the metabotropic glutamate receptor mGluR5. Proceedings of the National Academy of Science 2008, 105:12575-12580.
76. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
77. Lindsley C.W., Wisnoski D.D., Leister W.H., O'Brien J.A., Lemaire W., Williams D.L., Burno M., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Duggan M.E., Hartman G.D., Conn P.J., Huff J.R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. Journal of Medicinal Chemistry 2004, 47:5825-5828.
78. Liu F., Grauer S., Kelley C., Navarra R., Graf R., Zhang G., Atkinson P.J., Popiolek M., Wantuch C., Khawaja X., Smith D., Olsen M., Kouranova E., Lai M., Pruthi F., Pulicicchio C., Day M., Gilbert A., Pausch M.H., Brandon N.J., Beyer C.E., Comery T.A., Logue S., Rosenzweig-Lipson S., Marquis K.L. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. Journal of Pharmacology and Experimental Therapeutics 2008, 327:827-839.
79. Liu F., Zhang G., Hornby G., Vasylyev D., Bowlby M., Park K., Gilbert A., Marquis K., Andree T.H. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. European Journal of Pharmacology 2006, 536:262-268.
80. Lu W.Y., Xiong Z.G., Lei S., Orser B.A., Dudek E., Browning M.D., MacDonald J.F. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nature Neuroscience 1999, 2:331-338.
81. Lu Y.M., Jia Z., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., Roder J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. Journal of Neuroscience 1997, 17:5196-5205.
82. Luccini E., Musante V., Neri E., Brambilla Bas M., Severi P., Raiteri M., Pittaluga A. Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co expressed on rat and human noradrenergic terminals. British Journal of Pharmacology 2007, 151:1087-1094.
83. Malherbe P., Kew J.N.C., Richards J.G., Knoflach F., Kratzeisen C., Zenner M.-T., Faull R.L.M., Kemp J.A., Mutel V. Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Molecular Brain Research 2002, 109:168-178.
84. Mannaioni G., Marino M.J., Valenti O., Traynelis S.F., Conn P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. Journal of Neuroscience 2001, 21:5925-5934.
85. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Molecular Pharmacology 2010, 77:317-326.
86. Marenco S., Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Development and Psychopathology 2000, 12:501-527.
87. Marino M.J., Conn P.J. Direct and indirect modulation of the N-methyl d-aspartate receptor. Current Drug Targets. CNS and Neurological Disorders 2002, 1:1-16.
88. Matta J.A., Ashby M.C., Sanz-Clemente A., Roche K.W., Isaac J.T.R. mGluR5 and NMDA receptors drive the experience-and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron 2011, 70:339-351.
89. Matthysse S. Dopamine and the pharmacology of schizophrenia: the state of the evidence. Journal of Psychiatric Research 1974, 11:107.
90. McGrath J.J., Féron F.P., Burne T.H., Mackay-Sim A., Eyles D.W. The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Annals of Medicine 2003, 35:86-93.
91. Melchiorri D., Cappuccio I., Ciceroni C., Spinsanti P., Mosillo P., Sarichelou I., Sale P., Nicoletti F. Metabotropic glutamate receptors in stem/progenitor cells. Neuropharmacology 2007, 53:473-480.
92. Minakami R., Iida K., Hirakawa N., Sugiyama H. The expression of two splice variants of metabotropic glutamate receptor subtype 5 in the rat brain and neuronal cells during development. Journal of Neurochemistry 1995, 65:1536-1542.
93. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin in schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
94. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology 2010, 50:295-322.
95. Nyilas R., Gregg L.C., Mackie K., Watanabe M., Zimmer A., Hohmann A.G., Katona I. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. European Journal of Neuroscience 2009, 29:1964-1978.
96. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Molecular Brain Research 1998, 56:207-217.
97. Ohnuma T., Tessler S., Arai H., Faull R.L.M., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Molecular Brain Research 2000, 85:24-31.
98. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33:523-533.
99. Pałucha A., Brański P., Szewczyk B., Wierońska J.M., Kłak K., Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacology Biochemistry and Behavior 2005, 81:901-906.
100. Parmentier-Batteur S., Obrien J.A., Doran S., Nguyen S.J., Flick R.B., Uslaner J.M., Chen H., Finger E.N., Williams T.M., Jacobson M.A., Hutson P.H. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology 2012, 62:1453-1460.
101. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007, 13:1102-1107.
102. Pietraszek M., Gravius A., Schofer D., Weil T., Trifanova D., Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005, 49:73-85.
103. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106:579-587.
104. Polese D., de Serpis A.A., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of d-cycloserine. Neuropsychopharmacology 2002, 27:906-913.
105. Ramsey A.J. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Progress in Brain Research 2009, 179:51-58.
106. Rapoport J.L., Addington A.M., Frangou S., Psych M.R.C. The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry 2005, 10:434-449.
107. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., Meador-Woodruff J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biological Psychiatry 2000, 47:22-28.
108. Robbins T.W., Murphy E.R. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends in Pharmacological Sciences 2006, 27:141-148.
109. Rodriguez A.L., Grier M.D., Jones C.K., Herman E.J., Kane A.S., Smith R.L., Williams R., Zhou Y., Marlo J.E., Days E.L., Blatt T.N., Jadhav S., Menon U.N., Vinson P.N., Rook J.M., Stauffer S.R., Niswender C.M., Lindsley C.W., Weaver C.D., Conn P.J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Molecular Pharmacology 2010, 78:1105-1123.
110. Romano C., Pol V., den N.A., O'Malley K.L. Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution. The Journal of Comparative Neurology 1996, 367:403-412.
111. Romano C., Sesma M.A., McDonald C.T., O'malley K., van den Pol A.N., Olney J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. The Journal of Comparative Neurology 1995, 355:455-469.
112. Rondard P., Liu J., Huang S., Malhaire F., Vol C., Pinault A., Labesse G., Pin J.-P. Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. Journal of Biological Chemistry 2006, 281:24653-24661.
113. Ronesi J.A., Huber K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. Journal of Neuroscience 2008, 28:543-547.
114. Rosenbrock H., Kramer G., Hobson S., Koros E., Grundl M., Grauert M., Reymann K.G., Schröder U.H. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. European Journal of Pharmacology 2010, 639:40-46.
115. Schlumberger C., Pietraszek M., Gravius A., Danysz W. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacology Biochemistry and Behavior 2010, 95:23-30.
116. Schlumberger C., Pietraszek M., Gravius A., Klein K.U., Greco S., Moré L., Danysz W. Comparison of the mGlu5 receptor positive allosteric modulator ADX47273 and the mGlu2/3 receptor agonist LY354740 in tests for antipsychotic-like activity. European Journal of Pharmacology 2009, 623:73-83.
117. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002, 47:27-38.
118. Shao F., Han X., Li N., Wang W. Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats. European Journal of Pharmacology 2010, 649:202-205.
119. Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Alimentary Pharmacology and Therapeutics 2009, 29:731-741.
120. Sorensen S.D., Conn P.J. G protein-coupled receptor kinases regulate metabotropic glutamate receptor 5 function and expression. Neuropharmacology 2003, 44:699-706.
121. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews 2000, 24:417-463.
122. Spear N., Gadient R.A., Wilkins D.E., Do M., Smith J.S., Zeller K.L., Schroeder P., Zhang M., Arora J., Chhajlani V. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. European Journal of Pharmacology 2011, 659:146-154.
123. Spellmann I., Rujescu D., Musil R., Mayr A., Giegling I., Genius J., Zill P., Dehning S., Opgen-Rhein M., Cerovecki A., Hartmann A.M., Schafter M., Bondy B., Muller N., Moller H.J., Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Journal of Psychiatric Research 2011, 45:234-241.
124. Steele D., Moore R.L., Swan N.A., Grant J.S., Keltner N.L. Biological perspectives: the role of glutamate in schizophrenia and its treatment. Perspectives in Psychiatric Care 2012, 48:125-128.
125. Stefani M.R., Moghaddam B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. European Journal of Pharmacology 2010, 639:26-32.
126. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996, 128:371-379.
127. Tasker J.G., Boudaba C., Schrader L.A. Local glutamatergic and GABAergic synaptic circuits and metabotropic glutamate receptors in the hypothalamic paraventricular and supraoptic nuclei. Advances in Experimental Medicine and Biology 1998, 449:117.
128. Tatarczyńska E., Klodzińska A., Kroczka B., Chojnacka-Wójcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology 2001, 158:94-99.
129. Thomas U. Modulation of synaptic signalling complexes by Homer proteins. Journal of Neurochemistry 2002, 81:407-413.
130. Ting J.T., Peça J., Feng G. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annual Review of Neuroscience 2012, 35:49-71.
131. Toda M., Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Current Psychiatry Reports 2007, 9:329-336.
132. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology 2002, 42:165-179.
133. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., Doan A., Aakalu V.K., Lanahan A.A., Sheng M. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
134. Ugolini A., Corsi M., Bordi F. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999, 38:1569-1576.
135. Uslaner J.M., Parmentier-Batteur S., Flick R.B., Surles N.O., Lam J.S.H., McNaughton C.H., Jacobson M.A., Hutson P.H. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 2009, 57:531-538.
136. Vales K., Svoboda J., Benkovicova K., Bubenikova-Valesova V., Stuchlik A. The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801. European Journal of Pharmacology 2010, 639:91-98.
137. Van Den Pol A.N., Romano C., Ghosh P. Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. The Journal of Comparative Neurology 1995, 362:134-150.
138. Vardigan J.D., Huszar S.L., McNaughton C.H., Hutson P.H., Uslaner J.M. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?. Pharmacology Biochemistry and Behavior 2010, 95:223-229.
139. Vinson P.N., Conn P.J. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2012, 62:1461-1472.
140. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. American Journal of Psychiatry 2010, 167:1489-1498.
141. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Bubler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9:3897.
142. Wang H., Westin L., Nong Y., Birnbaum S., Bendor J., Brismar H., Nestler E., Aperia A., Flajolet M., Greengard P. Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science 2009, 326:1554-1557.
143. Williams R., Manka J.T., Rodriguez A.L., Vinson P.N., Niswender C.M., Weaver C.D., Jones C.K., Conn P.J., Lindsley C.W., Stauffer S.R. Synthesis and SAR of centrally active mGlu 5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorganic and Medicinal Chemistry Letters 2011, 21:1350-1353.
144. Wiseman Harris L., Sharp T., Gartlon J., Jones D.N., Harrison P.J. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. European Journal of Neuroscience 2003, 18:1706-1710.
145. Zhang Z., Sun Q.Q. Development of NMDA NR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Developmental Neurobiology 2010, 71:221-245.
146. Zhou Y., Manka J.T., Rodriguez A.L., Weaver C.D., Days E.L., Vinson P.N., Jadhav S., Hermann E.J., Jones C.K., Conn P.J., Lindsley C.W., Stauffer S.R. Discovery of N-aryl piperazines as selective mGluR 5 potentiators with improved in vivo utility. ACS Medicinal Chemistry Letters 2010, 1:433-438.
147. Zou D., Huang J., Wu X., Li L. Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats. Neuropharmacology 2007, 52:476-486.